Ali Nayfeh
Internal Medicine · Omaha, NENPI 1932655651
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (58.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 64.6% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $10,140, more than ten times the $169 reported in 2021. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $59.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- AstraZeneca$1K
- Boehringer Ingelheim$595
- Grifols USA, LLC$489
- GSK$319
- Astellas Pharma US Inc$234
- plus $2K from 19 others
What the payments were for
- Travel & lodging$1,0248%
- Food & beverage$4,21534%
- Education$7,23458%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $8,054 |
| AstraZeneca | 49 | $1,001 |
| Boehringer Ingelheim | 23 | $595 |
| Grifols USA, LLC | 20 | $489 |
| GSK | 18 | $319 |
| Astellas Pharma US Inc | 5 | $234 |
| Amgen | 10 | $221 |
| Insmed, Inc. | 15 | $216 |
| Sanofi | 7 | $197 |
| Harmony Biosciences LLC | 6 | $173 |
| Jazz Pharmaceuticals Inc. | 6 | $170 |
| Viatris Specialty LLC | 7 | $138 |
| Regeneron Healthcare Solutions, Inc. | 5 | $134 |
| AbbVie | 6 | $114 |
| Electromed, Inc. | 6 | $72 |
| Resmed Corp | 3 | $72 |
| Verona Pharma, Inc. | 4 | $63 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Abiomed | 1 | $47 |
| Philips North America LLC | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Gilead | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,994
How this compares
$12,473 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 453 | $325,161 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 319 | $154,597 |
| Spiriva RespimatTiotropium Bromide | 106 | $61,563 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 88 | $54,017 |
| Breo ElliptaFluticasone/Vilanterol | 111 | $44,744 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 73 | $39,976 |
| Incruse ElliptaUmeclidinium Bromide | 112 | $38,967 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 40 | $15,772 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $14,525 |
| Varenicline Tartrate | 54 | $14,406 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 51 | $13,312 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 390 | $10,728 |
| EliquisApixaban | 13 | $10,167 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $9,241 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $7,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $319 | $566,4821,007 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $595 | $107,065191 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $1,001 | $79,030150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Brian BoerOmaha$142K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
- Nikhil JaganOmaha$20K
- Clayton SchroederOmaha$14K
- Kirtibala GuptaOmaha$12K
- Chad VokounOmaha$11K
- Joel MichalskiOmaha$10K
- Sean McMillanOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.